Literature DB >> 3208245

Binding of heparin to antithrombin III: a chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-D-glucose residue.

M Petitou1, P Duchaussoy, I Lederman, J Choay, P Sinaÿ.   

Abstract

Known methyl (prop-1-enyl 2,3-di-O-benzyl-alpha-D-glucopyranosid)uronate was first converted into methyl (prop-1-enyl 2,3-di-O-benzyl-4-O-levulinyl-alpha-D-gluco-pyranosid)uro nat e. Acid hydrolysis, followed by treatment with (bromomethylene)-dimethylammonium bromide, gave methyl (2,3-di-O-benzyl-4-O-levulinyl-alpha-D-glucopyranosyl bromide)uronate. Condensation of this bromide with 1,6-anhydro-2-azido-3-O-benzyl-2-deoxy-beta-D-glucopyranose gave 1,6-anhydro-2-azido-3-O-benzyl-2-deoxy-4-O-(methyl 2,3-di-O-benzyl-4-O- levulinyl-beta-D-glucopyranosyluronate)-beta-D-glucopyranose. Acetolysis, followed by selective anomeric O-deacetylation and treatment with (bromomethylene)dimethylammonium bromide then gave 6-O-acetyl-2-azido-3-O-benzyl-2-deoxy-4-O-(methyl 2,3-di-O-benzyl-4-O-levulinyl -beta-D-glucopyranosyluronate)-alpha-D-glucopyranosyl bromide. Condensation of this bromide with benzyl 6-O-acetyl-3-O-benzyl-2-benzyloxycarbonylamino-2-deoxy-4- O-(methyl 2-O-acetyl-3-O-benzyl-alpha-L-idopyranosyluronate)-alpha-D- glucopyranoside provided benzyl O-(methyl 2,3-di-O-benzyl-4-O-levulinyl-beta-D- glucopyranosyluronate)-(1----4)-O-(6-O-acetyl-2-azido-3-O-benzyl-2-deoxy - alpha-D-glucopyranosyl)- (1----4)-O-(methyl 2-O-acetyl-3-O-benzyl-alpha-L-idopyranosyluronate)-(1----4)- 6-O-acetyl-3-O-benzyl-2-benzyloxycarbonylamino-2-deoxy-alpha-D-glu copyranoside. Removal of the levulinyl group followed by condensation with 6-O-acetyl-2-azido-3,4-di-O -benzyl-2-deoxy-alpha-D-glucopyranosyl bromide provided benzyl O-(6-O-acetyl-2- azido-3,4-di-O-benzyl-2-deoxy-alpha-D-glucopyranosyl)-(1----4)-O-(methyl 2,3-di- O-benzyl-beta-D-glucopyranosyluronate)-(1----4)-O-(6-O-acetyl-2-azido-3- O- benzyl-2- deoxy-alpha-D-glucopyranosyl)-(1----4)-O-(methyl 2-O-acetyl-3-O-benzyl-alpha-L- idopyranosyluronate)-(1----4)-6-O-acetyl-3-O-benzyl-2-benzyloxycarbon ylamino-2- deoxy-alpha-D-glucopyranoside in 78% yield. O-Deacetylation followed by re-esterification, O-sulfation, catalytic hydrogenolysis, saponification, and N-sulfation gave the non-sodium salt of O-(2-deoxy-6-O-sulfo-2-sulfoamino-alpha-D-glucopyranosyl)-(1----4) -O- (beta-D-glucopyranosyluronic acid)-(1----4)O-(2-deoxy-6-O-sulfo-2-sulfoamino- alpha-D-glucopyranosyl)-(1----4)-O-(2-O-sulfo-alpha-L-idopyranosyluronic acid)- (1----4)-2-deoxy-6-O-sulfo-2-sulfoamino-D-glucopyranose. This synthetic pentasaccharide neither binds to antithrombin III nor induces anti-factor Xa activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208245     DOI: 10.1016/0008-6215(88)84116-8

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  11 in total

1.  3-O sulfation of heparin leads to hepatotropism and longer circulatory half-life.

Authors:  Colton M Miller; Yongmei Xu; Katrina M Kudrna; Blake E Hass; Brianna M Kellar; Andrew W Egger; Jian Liu; Edward N Harris
Journal:  Thromb Res       Date:  2018-05-17       Impact factor: 3.944

2.  Asparagine 405 of heparin lyase II prevents the cleavage of glycosidic linkages proximate to a 3-O-sulfoglucosamine residue.

Authors:  Wenjing Zhao; Marie-Line Garron; Bo Yang; Zhongping Xiao; Jeffrey D Esko; Miroslaw Cygler; Robert J Linhardt
Journal:  FEBS Lett       Date:  2011-07-06       Impact factor: 4.124

Review 3.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

4.  Mass spectrometric method for determining the uronic acid epimerization in heparan sulfate disaccharides generated using nitrous acid.

Authors:  Vanessa Leah Gill; Qi Wang; Xiaofeng Shi; Joseph Zaia
Journal:  Anal Chem       Date:  2012-08-20       Impact factor: 6.986

5.  The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation.

Authors:  Benjamin Richard; Richard Swanson; Steven T Olson
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

6.  Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzymic polymer-modification reactions.

Authors:  M Kusche; H H Hannesson; U Lindahl
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

Review 7.  Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors:  L B Barradell; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 8.  Strategies in synthesis of heparin/heparan sulfate oligosaccharides: 2000-present.

Authors:  Steven B Dulaney; Xuefei Huang
Journal:  Adv Carbohydr Chem Biochem       Date:  2012       Impact factor: 12.200

9.  Characterization of heparin oligosaccharides binding specifically to antithrombin III using mass spectrometry.

Authors:  Hicham Naimy; Nancy Leymarie; Michael J Bowman; Joseph Zaia
Journal:  Biochemistry       Date:  2008-02-09       Impact factor: 3.162

Review 10.  Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.

Authors:  S Noble; D H Peters; K L Goa
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.